BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 19, Issue 37
  • This Article
Peer-Review Report of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2013; 19(37): 6144-6155
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6144
Table 1 Molecular targets and therapeutic agents
Molecular targetsTherapeutic agents
VEGF/VEGFRSorafenib
Bevacizumab
Vatalanib (PTK787)
Cediranib (AZD2171)
Brivanib
Sunitinib
Linifanib (ABT869)
EGF/EGFRCetuximab
Erlotinib
Lapatinib
IGF/IGFROSI-906
IMC-A12
AVE1642
BIIB022
Ras/Raf/MEK/ERKSorafenib
Selumetinib (AZD6244)
PI3K/Akt/mTORAZD8055
Everolimus
Sirolimus
Temsirolimus
Wnt-β-cateninPFK118-310
PFK115-584
CGP049090
METTivanitib
EGF: Epidermal growth factor; EGFR: EGF receptor; ERK: Extracellular signal-regulated kinase; FGFR: Fibroblast growth factor receptor; IGFR: Insulin-like growth factor (IGF) receptor; VEGF: Vascular endothelial growth factor; VEGFR: VEGF receptor; mTOR: Mammalian target of rapamycin; MET: Met proto-oncogene.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.